Long-Term Outcomes of Anatomic Versus Nonanatomic Resection in Hepatocellular Carcinoma Patients with Bile Duct Tumor Thrombus: A Propensity Score Matching Analysis.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
13
10
2020
accepted:
28
02
2021
pubmed:
1
5
2021
medline:
21
10
2021
entrez:
30
4
2021
Statut:
ppublish
Résumé
Anatomic resection (AR) of the liver is generally recommended in hepatocellular carcinoma (HCC) patients. However, the benefits of AR and nonanatomic resection (NAR) in HCC patients with bile duct tumor thrombus (BDTT) are unknown. This study aimed to compare long-term outcomes of AR and NAR in HCC patients with BDTT after curative resection. A total of 175 consecutive HCC patients with BDTT after curative resection between April 2009 and December 2017 were included. One-to-one propensity score matching (PSM) was performed to minimize the influence of potential confounders. Recurrence-free survival (RFS) and overall survival (OS) were compared between the cohorts. After PSM, 120 patients were analyzed. The AR group had better RFS than the NAR group (P = 0.010). Even though there was no statistically significant difference in OS (P = 0.140, power = 0.33), the 3- and 5-year OS rates in the AR group (52.4% and 44.2%, respectively) were obviously higher than those in the NAR group (35.4% and 30.4%, respectively). When patients were further stratified according to tumor size, better RFS and OS were observed in patients with small (≤ 5 cm) tumors after AR (P < 0.001 and P = 0.004, respectively). Multivariate analysis identified AR (P = 0.024) as an independent favorable prognostic factor for RFS in HCC patients with BDTT. AR is recommended for HCC patients with BDTT, especially in patients with small (≤ 5 cm) tumors.
Sections du résumé
BACKGROUND
BACKGROUND
Anatomic resection (AR) of the liver is generally recommended in hepatocellular carcinoma (HCC) patients. However, the benefits of AR and nonanatomic resection (NAR) in HCC patients with bile duct tumor thrombus (BDTT) are unknown. This study aimed to compare long-term outcomes of AR and NAR in HCC patients with BDTT after curative resection.
PATIENTS AND METHODS
METHODS
A total of 175 consecutive HCC patients with BDTT after curative resection between April 2009 and December 2017 were included. One-to-one propensity score matching (PSM) was performed to minimize the influence of potential confounders. Recurrence-free survival (RFS) and overall survival (OS) were compared between the cohorts.
RESULTS
RESULTS
After PSM, 120 patients were analyzed. The AR group had better RFS than the NAR group (P = 0.010). Even though there was no statistically significant difference in OS (P = 0.140, power = 0.33), the 3- and 5-year OS rates in the AR group (52.4% and 44.2%, respectively) were obviously higher than those in the NAR group (35.4% and 30.4%, respectively). When patients were further stratified according to tumor size, better RFS and OS were observed in patients with small (≤ 5 cm) tumors after AR (P < 0.001 and P = 0.004, respectively). Multivariate analysis identified AR (P = 0.024) as an independent favorable prognostic factor for RFS in HCC patients with BDTT.
CONCLUSIONS
CONCLUSIONS
AR is recommended for HCC patients with BDTT, especially in patients with small (≤ 5 cm) tumors.
Identifiants
pubmed: 33929619
doi: 10.1245/s10434-021-09874-3
pii: 10.1245/s10434-021-09874-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7686-7695Subventions
Organisme : Natural Sicience Foundation of Fujian Province
ID : 2020J011105
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021. Society of Surgical Oncology.
Références
Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
doi: 10.3322/caac.21262
Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2019;394:1145–58.
doi: 10.1016/S0140-6736(19)30427-1
Qin LX, Tang ZY. Hepatocellular carcinoma with obstructive jaundice: diagnosis, treatment and prognosis. World J Gastroenterol. 2003;9:385–91.
doi: 10.3748/wjg.v9.i3.385
Kim DS, Kim BW, Hatano E, et al. Surgical outcomes of hepatocellular carcinoma with bile duct tumor thrombus: a Korea-Japan multicenter study. Ann Surg. 2020;271:913–21.
doi: 10.1097/SLA.0000000000003014
Wong TCL, Cheung TT, Chok KSH, et al. Outcomes of hepatectomy for hepatocellular carcinoma with bile duct tumour thrombus. HPB. 2014;17:401–8.
doi: 10.1111/hpb.12368
Shiomi M, Kamiya J, Nagino M, et al. Hepatocellular carcinoma with biliary tumor thrombi: aggressive operative approach after appropriate preoperative management. Surgery. 2001;129:692–8.
doi: 10.1067/msy.2001.113889
Qiao WH, Yu F, Wu LP. Surgical outcomes of hepatocellular carcinoma with biliary tumor thrombus: a systematic review. BMC Gastroenterol. 2016;16:11.
doi: 10.1186/s12876-016-0427-2
Esaki M, Shimada K, Sano T, et al. Surgical results for hepatocellular carcinoma with bile duct invasion: a clinicopathologic comparison between macroscopic and microscopic tumor thrombus. J Surg Oncol. 2005;90:226–32.
doi: 10.1002/jso.20260
Famularo S, Ceresoli M, Giani A, et al. Is it just a matter of surgical extension to achieve the cure of hepatocarcinoma? A meta-analysis of propensity-matched and randomized studies for anatomic versus parenchyma-sparing liver resection. J Gastrointest Surg. 2021;25:94–103.
doi: 10.1007/s11605-019-04494-5
Zhong XP, Zhang YF, Mei J, et al. Anatomical versus non-anatomical resection for hepatocellular carcinoma with microscope vascular invasion: a propensity score matching analysis. J Cancer. 2019;10:3950–7.
doi: 10.7150/jca.32592
Zeng H, Xu LB, Wen JM, et al. Hepatocellular carcinoma with bile duct tumor thrombus: a clinicopathological analysis of factors predictive of recurrence and outcome after surgery. Medicine (Baltimore). 2015;94:e364.
doi: 10.1097/MD.0000000000000364
Iizuka N, Oka M, Yamada-Okabe H, et al. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet. 2003;361:923–9.
doi: 10.1016/S0140-6736(03)12775-4
Portolani N, Coniglio A, Ghidoni S, et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg. 2006;243:229–35.
doi: 10.1097/01.sla.0000197706.21803.a1
Makuuchi M, Hasegawa H, Yamazaki S. Ultrasonically guided subsegmentectomy. Surg Gynecol Obstet. 1985;161:346–50.
pubmed: 2996162
Zhou XQ, Wang JF, Tang MM, et al. Hepatocellular carcinoma with hilar bile duct tumor thrombus versus hilar cholangiocarcinoma on enhanced computed tomography: a diagnostic challenge. BMC Cancer. 2020;20:54.
doi: 10.1186/s12885-020-6539-7
Yamamoto S, Hasegawa K, Inoue Y, et al. Bile duct preserving surgery for hepatocellular carcinoma with bile duct tumor thrombus. Ann Surg. 2015;261:e123–5.
doi: 10.1097/SLA.0000000000001209
Kasai Y, Hatano E, Seo S, et al. Hepatocellular carcinoma with bile duct tumor thrombus: surgical outcomes and the prognostic impact of concomitant major vascular invasion. World J Surg. 2015;39:1485–93.
doi: 10.1007/s00268-015-2985-9
Iguchi T, Shirabe K, Aishima S, et al. New pathologic stratification of microvascular invasion in hepatocellular carcinoma: predicting prognosis after living-donor liver transplantation. Transplantation. 2015;99:1236–42.
doi: 10.1097/TP.0000000000000489
Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 1954;7:462–503.
doi: 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E
Amin MB, Greene FL, Edge SB, et al (2017) The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin.; 67:93–99.
Peng BG, Liang LJ, Li SQ, et al. Surgical treatment of hepatocellular carcinoma with bile duct tumor thrombi. World J Gastroenterol. 2005;11:3966–9.
doi: 10.3748/wjg.v11.i25.3966
Qin LX, Ma ZC, Wu ZQ, et al. Diagnosis and surgical treatments of hepatocellular carcinoma with tumor thrombosis in bile duct: experience of 34 patients. World J Gastroenterol. 2004;10:1397–401.
doi: 10.3748/wjg.v10.i10.1397
Shindoh J, Makuuchi M, Matsuyama Y, et al. Complete removal of the tumor-bearing portal territory decreases local tumor recurrence and improves disease-specific survival of patients with hepatocellular carcinoma. J Hepatol. 2016;64:594–600.
doi: 10.1016/j.jhep.2015.10.015
Ishii M, Mizuguchi T, Kawamoto M, et al. Propensity score analysis demonstrated the prognostic advantage of anatomical liver resection in hepatocellular carcinoma. World J Gastroenterol. 2014;20:3335–42.
doi: 10.3748/wjg.v20.i12.3335
Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011;10:150–61.
doi: 10.1002/pst.433
Cohen J. A power primer. Psychol Bull. 1992;112:155–9.
doi: 10.1037/0033-2909.112.1.155
Rammohan A, Sathyanesan J, Rajendran K, et al. Bile duct thrombi in hepatocellular carcinoma: is aggressive surgery worthwhile? HPB (Oxford). 2015;17:508–13.
doi: 10.1111/hpb.12383
Orimo T, Kamiyama T, Yokoo H, et al. Hepatectomy for hepatocellular carcinoma with bile duct tumor thrombus, including cases with obstructive jaundice. Ann Surg Oncol. 2016;23:2627–34.
doi: 10.1245/s10434-016-5174-7
Kim JM, Kwon CHD, Joh JW, et al. Incidental microscopic bile duct tumor thrombi in hepatocellular carcinoma after curative hepatectomy: a matched study. Medicine (Baltimore). 2015;94:e450.
doi: 10.1097/MD.0000000000000450
Moon DB, Hwang S, Wang HJ, et al. Surgical outcomes of hepatocellular carcinoma with bile duct tumor thrombus: a Korean multicenter study. World J Surg. 2013;37:443–51.
doi: 10.1007/s00268-012-1845-0
Oba A, Takahashi S, Kato Y, et al. Usefulness of resection for hepatocellular carcinoma with macroscopic bile duct tumor thrombus. Anticancer Res. 2014;34:4367–72.
pubmed: 25075073
Yeh CN, Jan YY, Lee WC, et al. Hepatic resection for hepatocellular carcinoma with obstructive jaundice due to biliary tumor thrombi. World J Surg. 2004;28:471–5.
doi: 10.1007/s00268-004-7185-y
Wang DD, Wu LQ, Wang ZS. Prognosis of hepatocellular carcinoma with bile duct tumor thrombus after R0 resection: a matched study. Hepatobiliary Pancreat Dis Int. 2016;15:626–32.
doi: 10.1016/S1499-3872(16)60143-1
Okamura Y, Ito T, Sugiura T, et al. Anatomic versus nonanatomic hepatectomy for a solitary hepatocellular carcinoma: a case-controlled study with propensity score matching. J Gastrointest Surg. 2014;18:1994–2002.
doi: 10.1007/s11605-014-2646-6